PTC THERAPEUTICS Business Summary

PTC Therapeutics (PTCT) operates as a commercial-stage biopharmaceutical firm specializing in rare disorders, generating revenue through direct product sales, milestone payments, and tiered royalties. Its primary business segments are categorized by therapeutic modality: the Duchenne muscular dystrophy (DMD) franchise, led by Emflaza and Translarna; the spinal muscular atrophy (SMA) royalty stream from Evrysdi (partnered with Roche); and its emerging gene therapy portfolio, headlined by Upstaza for AADC deficiency. The company utilizes a diversified technology platform to address high-unmet-need populations, leveraging both small-molecule RNA modulation and gene therapy delivery systems. PTC faces direct competition from Sarepta Therapeutics in the DMD market, Biogen and Novartis in the SMA space, and Vertex Pharmaceuticals in the broader orphan drug sector. Relative to these peers, PTC occupies a strategic position as a diversified mid-cap leader with a unique dual focus on post-transcriptional control and advanced genetic medicines. The company was founded in 1998 by Dr. Stuart Peltz, a pioneer in mRNA biology who served as CEO for 25 years. Today, the leadership team is headed by Chief Executive Officer Dr. Matthew B. Klein, who previously served as the company’s Chief Development Officer and joined the firm via the acquisition of BioElectron Technology. The executive suite includes Chief Financial Officer Pierre Gravier, who brings a background in healthcare investment banking from Perella Weinberg Partners, and Chief Commercial Officer Eric Pauwels, a veteran in global orphan drug commercialization. PTC’s strategic direction is overseen by a board of directors that includes Chairman Dr. Kerwin Hoffman and is supported by significant institutional investors such as BlackRock, Vanguard, and Dodge & Cox. This leadership pedigree combines foundational scientific innovation in mRNA regulation with the operational expertise required to scale a global commercial rare disease enterprise.